Organ specific tumor markers: What's new?
Publication Type:Journal Article
Source:Indian Journal of Clinical Biochemistry, Volume 27, Number 2, p.110-120 (2012)
Keywords:acid phosphatase prostate isoenzyme, alpha fetoprotein, bladder cancer, body fluid, breast cancer, CA 125 antigen, CA 19-9 antigen, cancer screening, carbohydrate antigen, chorionic gonadotropin beta subunit, colorectal cancer, cyclin E, cytokeratin, DNA topoisomerase (ATP hydrolysing), enzyme linked immunosorbent assay, epidermal growth factor receptor 2, esophagus cancer, estradiol, estrogen receptor, Gene expression profiling, head and neck cancer, human, immunohistochemistry, inhibin, kidney cancer, liver cancer, lung cancer, lymphoma, Melanoma, micrometastasis, mouth cancer, mucin like carcinoma associated antigen, Muellerian inhibiting factor, neuron specific enolase, nonhuman, pancreas cancer, progesterone receptor, prostate cancer, protein S 100, proteomics, radioimmunoassay, Reliability, review, sensitivity and specificity, squamous cell carcinoma antigen, stomach cancer, telomerase reverse transcriptase
Tumor markers are molecules produced in the body in response to cancer. An ideal tumor marker should have high sensitivity and specificity, should be cheap, and should be easily detected in body fluids. Identification of novel markers is important and it is expected that with the advent of newer technologies, more reliable markers will be discovered. This review discusses the currently available tumor markers for different malignancies. © 2012 Association of Clinical Biochemists of India.
cited By 7
Cite this Research Publication
Related Research Publications
- Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer
- Diagnostic utility of PETCT in thyroid malignancies: An update
- Innovative method for quantification of cell-cell adhesion in 96-well plates
- PET/CT in the evaluation of anti-NMDA-receptor encephalitis: What we need to know as a NM physician
- Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine